PubMed, EMBASE, Orphanet, MIDLINE, Google Scholar and Cochrane Library were searched for articles published between 1983 and 2015. Relevant articles were selected by using the following terms: "Liver cirrhosis", "Endothelial dysfunction", "Sinusoidal remodeling", "Intrahepatic angiogenesis" and "Pathogenesis of portal hypertension". Then the reference lists of identified articles were searched for other relevant publications as well. Besides gross hepatic structural disorders related to diffuse fibrosis and formation of regenerative nodules, the complex morphofunctional rearrangement of the hepatic microvascular bed and intrahepatic angiogenesis also play important roles in hemodynamic disturbances in liver cirrhosis. It is characterized by endothelial dysfunction and impaired paracrine interaction between activated stellate hepatocytes and sinusoidal endotheliocytes, sinusoidal remodeling and capillarization, as well as development of the collateral microcirculation. In spite of the fact that complex morphofunctional rearrangement of the hepatic microvascular bed and intrahepatic angiogenesis in liver cirrhosis are the compensatory-adaptive reaction to the deteriorating conditions of blood circulation, they contribute to progression of disease and development of serious complications, in particular, related to portal hypertension.
of the hepatic microvascular bed and intrahepatic angiogenesis play important roles in hemodynamic disturbances in liver cirrhosis. In spite of the fact that these changes of the hepatic vasculature are the compensatory-adaptive reaction to the deteriorating conditions of blood circulation, they contribute to the progression of disease and development of serious complications, in particular, related to portal hypertension.
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MORPHOFUNCTIONAL

REARRANGEMENT OF THE HEPATIC MICROVASCULAR BED IN LIVER CIRRHOSIS
Besides gross hepatic structural disorders related to diffuse fibrosis and formation of regenerative nodules, the complex morphofunctional rearrangement of the hepatic microvascular bed in liver cirrhosis also con tributes to the development of severe complications, in particular, associated with portal hypertension [1] . In this situation, the main place of resistance to portal blood flow is in pathologically modified sinusoids. Sinusoidal endothelial cells (SEC) become dysfunctional and among other features acquire a vasoconstrictor phenotype. It leads to increasing of SEC sensitivity to endogenous vasoconstrictors, such as endothelin, norepinephrine, angiotensin Ⅱ, vasopressin, leukotrienes, thromboxane A2. In contrast, the production of nitric oxide (the most studied vasodilator involved in the regulation of hepatic vascular tone) is reduced. The reason for this may be insufficient activity of endothelial nitric oxide synthase (eNOS) due to its increased interaction with caveolin1. Furthermore, endotelin1 activates Gproteincoupled receptor kinase2 which directly interacts with and inhibits protein kinase B (Akt) phosphorylation and decreases the production of nitric oxide (NO) [2] . One of the main factors of sinusoidal endothelial dysfunction in cirrhosis is intrahepatic oxidative stress, which is associated with a decrease of eNOS expression and NO bioavailability. For example, cyclooxygenase attenuates AkteNOS signalization by stimulating thromboxane A2, which inhibits Akt phosphorylation in endothelial cells, as well as excessive activation of Rho kinase. Asymmetric dimethylarginine, an endogenous inhibitor of NOS, causes uncoupling of NOS leading to generation of reactive nitrogen species such as peroxynitrite, and downregulated tetrahydrobiopterin expression promotes that the eNOS cannot generate NO but instead produces O2 , thereby leading to further decreases in NO production. In addition, it was reported that a possible reason for the insufficient bioavailability of nitric oxide might be a reduction of superoxide dismutase ("an enzyme that saves NO") and increase of homocysteine level in the serum due to reduced expression of cystathionineγlyase and cystathionineβ syntase [3] . Activated hepatic stellate cells (HSCs) and its paracrine interaction with SEC play very important roles in the sinusoidal microcirculation in liver cirrhosis. In pathological conditions violation of the structure and function of HSCs accompanied by a loss of retinoids reserve and HSCs transformation into myofibroblasts. Activated HSCs start to perform the functions of pericytes. This is confirmed by the expression of its phenotypic markers such as αsmooth muscle actin, desmin, NG2, glial fibrillary acidic protein, as well as emergence or increase of receptors for growth factors, cytokines and endothelin, and a number of cell adhesion molecules on its surface [4] . HSCs, located in the subendothelial Disse spaces between the SEC and hepatocytes, are contacted because of the long branching cytoplasmic processes with nerve endings, which contains various neurotrans mitters such as substance P, vasoactive intestinal pep tide, somatostatin, cholecystokinin, neurotensin, NO, calcitonin generelated peptide, and neuropeptide Y. Some vasoactive substances are able to regulate the tone of HSCs. Substances for instance endothelin1, substance P, angiotensin Ⅱ, norepinephrine, prosta glandin F2, thromboxane A2, platelet activating factor (PAF) and thrombin can trigger HSC contractility. In contrast, vasoactive substances such as acetylcholine, vasoactive intestinal peptide, NO, carbon monoxide, hydrogen sulfide, prostaglandin E2, and adrenomedullin are known for the ability to relax HSCs [5] . independent pathway, Rho kinase and protein kinase C inhibit the activity of myosin light chain phosphatase, an enzyme that depho sphorylates phosphorylated myosin light chains and induces relaxation [6] . Endothelin (ET) as a powerful endogenous vaso constrictor modulates the tone of the HSCs. ET has three kinds of isoform, ET1, 2, and 3, which are synthe sized from ET by endothelinconverting enzymes. They interact with conjugated protein G receptors A and B types, which are well expressed in the HSCs. ET1 is the most studied. The main site of its synthesis in liver cirrhosis is activated HSCs. Stimulation of endothelin A receptors leads to its proliferation [7] . Angiotensin Ⅱ has a similar effect. In liver cirrhosis, HSCs increase its synthesis because of increased expression of angiotensinconverting enzyme. HSCs constriction may also be caused by decreased NO production and/or bioavailability in cirrhotic liver [8] . In contrast, carbon monoxide overproduction by Kupffer cells causes a dilation of the sinusoids and a decrease of hepatic vascular resistance (HVR) because of paracrine impact on HSCs and SEC [9] . Increased HSCs mobility and migration in liver cirrhosis are required to promote enhanced coverage of HSCs around an EClined sinusoid, contributing to the process of sinusoidal remodeling [10] . Changes in the structure of the HSCs membrane plays an important role in this process. Cellular locomotion requires dynamic but regulated actin remodeling to form membrane structures that facilitate cell extension. These include lamellipodia, which are membrane protrusions that form the leading edge toward directed cell migration, and filopodia, which are thin, actin filamentstructured spikes emanating from the plasma membrane. Small guanosine triphosphatases from the Rho family including RhoA (Rho), Rac1 (Rac), and Cdc42 in turn, closely regulate formation of actinbased structures. Proved that if Rac contributes to HSC migration due to formation of filopodia, the Rho causes a resistant to the inhibitory action of NO and restores the chemotactic response to plateletderived growth factor (PDGF) in the absence of a functional Rac [11] . A key molecule responsible for proliferation, mig ration, mobility and recruitment of HSCs is PDGF, which is secreted by endothelial cells and binds to its cognate PDGF receptor (PDGFRβ) on pericytes, in particular due to an ephrinB2/EphB4 signaling pathway [12] . Moreover, activation of the PDGFRβ causes to stimulation of Raf1 kinase, MEK kinase and extracellularsignal regulated kinase (ERK), which leads to the proliferation of the HSCs. Phosphatidylinositol 3kinase activation is also necessary for both mitogenesis and chemotaxis induced by PDGF [13] . In addition, it is shown that the axonal guidance molecule neuropilin1 contributes to the chemo tactic response to PDGF too [14] . Activated HSCs are a rich source of polypeptides, eicosanoids and various other molecules with paracrine, juxtacrine, and autocrine signalization or chemoattrac tant activity, which include: (1) polypeptides which enhance cells proliferation in an autocrine and paracrine manner: Hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), endothelin1, insulin like growth factor, transforming growth factor (TGF)α, epidermal growth factor (EGF) and acidic fibroblast growth factor (aFGF); (2) members of the TGFβ family; (3) neurotrophins; and (4) hematopoietic growth factors such as erythropoietin [15] . When the liver is damaged, activated HSC pro liferate and migrate to areas of inflammation and necrosis of hepatocytes, producing excessive amounts of extracellular matrix components. TGFβ1, PDGF, connective tissue growth factor and FGF regulate this process [16] .
Overall there are three general sources of fibrogenic cells in the liver: (1) endogenous (resident) fibroblast or myofibroblastlike cells, mainly represented by HSCs, but also by portal fibroblast, vascular smooth muscle cells and pericytes; (2) the epithelialmesenchymal transition that may occur in the liver as well as in other organs and lead to transdifferentiation of parenchymal cells; and (3) recruitment of fibrocytes from the bone marrow [17] .
INTRAHEPATIC ANGIOGENESIS IN LIVER CIRRHOSIS
In 1983, Rappaport et al [18] were among the first who had described the collateral microcirculation in cirrhotic liver. Nowadays, pathological angiogenesis well characterized in experimental liver fibrosis, as well as in patients with chronic viral and autoimmune liver diseases and nonalcoholic steatohepatitis [19] . Angiogenesis is the complicated physiological pro cess through which new blood vessels form from pre existing vessels. It is accomplished by the activation of endothelial cells, expression in it proteases, destruction of the extracellular matrix, proliferation, migration of the endothelial cells and formation of high permeability primary vascular structures [20] .
Molecular insights into the angiogenic process
The primary inducer of angiogenesis in physiological and pathological conditions is hypoxia. Cells respond to hypoxic stress through multiple mechanisms, including the stabilization of hypoxiainducible factors (HIFs), which directly regulate the expression of angiogenic growth factors. The family of HIFs includes three αsubunits, which are associated with a common βsubunit (HIF1β). HIF1α appears to be ubiquitously expressed, whereas HIF2α is detected in a more restricted set of cell types, including vascular endothelial cells, hepatocytes, type Ⅱ pneumocytes, and macrophages. A third mammalian HIFα subunit, HIF3α, has also been described, although its role in hypoxic responses is less well understood [21] . NADPH oxidase is an important mediator of ang iogenic signaling pathways. It was noted that the incre ased NADPH oxidase expression because of NADPH oxidase subunit p 47phox phosphorylation leads to an increase in the reactive oxygen species (ROS) levels, contributing to HIF1α induction, VEGFreceptors (VEGFR) activation and EGFreceptors transactivation [22] . The important role of miRNA has been shown re cently in the regulation of cellular response to hypoxia. In particular, Let7 and miR103/107 favor the VEGF induction by targeting argonaute 1 protein [23] .
The most studied angiogenic growth factors include have shown that it may induce the formation of blood vessels and regulate their tone [26] . Tie2 (Tek), an endothelialspecific receptor tyrosine kinase, and its ligands, the angiopoietins, have been identified as critical mediators of vascular development. Angiopoetin1 induces endothelial cells migration, inhibits endothelial cells apoptosis and stimulates its formation, promoting stabilization of vessels. At the same time, NADPH oxidase is involved in the ang 1mediated activation of Akt and mitogenactivated protein kinase (p42/p44 MAPK, or ERK2 and ERK1) and subsequent modulation of endothelial cell migration and angiogenesis [27] . In contrast, angiopoietin2 causes vascular destabilization by shifting the endothelial cells from the stable state to the proliferative phenotype. However, it may also stimulate angiogenesis in the presence of VEGF [28] . Integrin αVβ3 and αVβ5 are adhesion receptors promoting angiogenesis by mediating migration and proliferation of endothelial cells and the formation of new blood vessels [29] . Endothelialspecific adhesion molecule vascular endothelial cadherin contributes to cellcell junctions during neovascularization and controls the passage of molecules through the endothelial lining [30] . Thrombospondin1 one of the five known thrombo spondins is an adhesive protein that regulates the interaction of cells with each other and with the extra cellular matrix. Its expression increases with the progression of liver cirrhosis and strongly correlated with the severity of fibrosis and angiogenesis. However, the precise role of thrombospondin1 is not defined in this process. It may function as a promoter or inhibitor of angiogenesis that may depend on its concentration, the type of domain being activated and the type of receptors present on endothelial cells [31] . Angiostatin a fragment of plasminogen, and endostatin a fragment of the Cterminal part of the collagen ⅩⅧ α1chain, inhibits the migration of human endothelial cells stimulated with FGF and VEGF and do not affect intracellular signaling pathways stimulated by FGF and VEGF [32] . Tolllike receptor 4, which recognizes bacterial lipopolysaccharide, is expressed by SECs involved in fibrosisassociated angiogenesis in cirrhotic liver. These properties are related through the cytosolic adapter protein MyD88, which is involved in the production of extracellular protease regulating the invasive ability of SECs [33] . Hepatic apelin system (apelin/APJreceptor) the connecting link between chronic inflammation and subsequent fibrogenic and angiogenic processes in liver cirrhosis. On the one hand, hypoxia and inflammation initiate expression of APJ, on the other profibrogenic activation of APJ mediates the induction of profibrogenic genes, HSCs proliferation and secretion of proangiogenic factors [34] . Aquaporin1 is an integral membrane channel pro VEGF family consisting of five homologs: VEGFA, B, C, D and placental growth factor (PlGF). VEGF stimulates both physiological and pathological angiogenesis. All members of this family are connected to different homologous receptors: VEGFR1 (Flt1), VEGFR2 (KDR/ Flk1), VEGFR3 (Flt4), of which only the first and second responsible for angiogenic signals transmitting. Besides that, the binding of VEGAA to VEGFR2 and increasing vascular permeability through the nitric oxide are the mechanisms triggering angiogenesis and vasculogenesis.
PlGF, a homolog of VEGF binding VEGFR1, enhances angiogenesis, but only in pathological conditions affe cting, directly and indirectly, multiple cell types, including endothelial cells. In addition, it is assumed that PlGF, breaking the binding of VEGF with VEGFR1, makes the binding of VEGF with VEGFR2 more probable. Mass spectrometry studies showed that PlGF and VEGF each induce the phosphorylation of distinct tyrosine residues in VEGFR1, further indicating that PlGF and VEGF transmit distinct angiogenic signals through VEGFR1.
Different mechanisms are the basis of synergism between PlGF and VEGF. By activating VEGFR1, PlGF induces an intermolecular cross talk between VEGFR1 and VEGFR2, which thereby is more response to VEGF. PlGF, as a subunit of PlGF/VEGF heterodimer, induces the formation of VEGFR1/2 heterodimers, which trans phosphorylate each other in an intramolecular reaction. By producing PlGF, endothelial cells are thus capable of enhancing their own responsiveness to VEGF but adjacent stromal or inflammatory cells may also release PlGF.
PlGF directly affects smooth muscle cells and fibro blasts, which express VEGFR1, but may also indirectly influence its proliferation and migration through cytokine release from activated endothelial cells. Through these effects, PlGF recruits smooth muscle cells around nascent vessels, thereby stabilizing them into mature, durable and nonleaky vessels.
PlGF also mobilizes VEGFR1 positive hematopoietic progenitor cells from the bone marrow and recruits, indirectly via upregulation of VEGF expression, VEGFR 2positive endothelial progenitor cells to the ischemic tissue. PlGF is also chemoattractive for monocytes and macrophages, which express VEGFR1 [24] . FGF family members are also able to stimulate angiogenesis. Cellular response to FGFs occurs through specific binding FGFreceptor (FGFR), which has internal tyrosine kinase activity. FGFR dimerization is a prerequisite for phosphorylation and activation of signaling molecules with the participation of heparin binding proteins. This causes migration, proliferation, cell differentiation and destruction of extracellular matrix. It should be noted that while VEGF family members are involved mainly in the formation of the capillaries, FGFs primarily involved in arteriogenesis [25] . Although the angiogenic effect of PDGF is not so expressed as in VEGF, PIGF and FGF, studies in vivo tein, overexpressed in cirrhosis, that promotes angio genesis by enhancing endothelial invasion [35] . It is known that chemokines from CXC family are involved in angiogenesis. ELRpositive chemokines stimulate this process, and ELRnegative suppress it [36] . Neuropilin1 and neuropilin2 are transmembrane glycoproteins with large extracellular domains that interact with both class 3 semaphorins, VEGF and the classical receptors for VEGF, VEGFR1 and 2, mediating signal transduction. Neuropilin1 expressed mainly by arterial endothelium, whereas neuropilin2 is only expressed by venous and lymphatic endothelium. Both neuropilins are commonly overexpressed in regions of physiological and pathological angiogenesis, but the definitive role of neuropilins in angiogenic processes are not fully characterized [37] .
Mechanisms of intrahepatic angiogenesis in liver cirrhosis
Hepatic angiogenesis may substantially differ from homologous processes in other organs or tissue on the basis of: (1) the rather unique phenotypic profile and functional role of activated HSCs and of other liver myofibroblasts; (2) the presence of two different micro vascular structures described (i.e., sinusoids lined by fenestrated endothelium vs large vessels lined by a continuous one); and (3) the existence of ANGPTL3, a liverspecific angiogenic factor.
There are two main ways of forming new blood vessels in liver cirrhosis [38] (Figure 1) . One of them is associated with increased expression of proangiogenic growth factors, cytokines and matrix metalloproteinases on the background of chronic inflammation [39] . Proin flammatory mediators produced by Kupffer cells, mast cells and leukocytes may produce angiogenic response due to induction and increased transcriptional activity of HIF1α [40] . It is believed that macrophages in the normal state are not directly involved in angiogenesis. In contrast, activated Kupffer cells contribute to the formation of new blood vessels through the production of cytokines, ROS and PAF in liver cirrhosis [41] . Kupffer cells also produce tumor necrosis factorα (TNFα), which induces the migration of cells and re gulates apoptosis and angiogenesis [42] . The increase of ROS in the liver stimulates angiogenesis due to enhanced expression of TNFα, NO, HIF1 and VEGF [43] . PAF promotes the development of VEGF by the activation of nuclear transcription factor nuclear factor kB (NFkB) [44] . Mast cells involved in the formation of new blood vessels through the production of heparin, histamine, tryptase, cytokines (TGFβ1, TNFα, interleukins) and VEGF. They can also increase the number of SECs in vitro [45] . Soluble mediators, in particular, proinflammatory cytokines, growth factors, proteases, and products of oxidative stress regulate increased expression of chemokines in chronic inflammation of the liver. Leukocytes can thereby penetrate into the liver tissue where they produce angiogenic factors such as VEGF, PIGF, PDGF, FGF, TGFβ1, EGF, angiopoietin2 and different interleukins [46] . On the one hand, hypoxia, caused by HIF1α stimu lation, activates the HSCs and leads to the production of various angiogenic and fibrogenic factors (PIGF, VEGF, NO, HGF, PDGF) [47] , promoting angiogenesis and progression of hepatic fibrosis [48] . On the other hand, diffuse fibrosis, regenerative liver nodules and forming of sinusoidal capillarization cause an increase of HVR and impair the oxygen supply to the liver cells [49] . Accumulation of HIFs, in particular, HIF1α, increases the VEGF, angiopoietin1 and their receptors expression on activated HSCs. This leads to involvement and sti mulation of SECs, stabilizing the newly formed vessels and providing them with strength [50] . In turn, SECs generate PDGF and TGFβ, helping to attract and migration of HSCs. This process includes ROSmediated activation of ERK and cJunNH2terminal kinase (JNK) followed by a delayed and HIF1αdependent up regulation and release of VEGF [51] .
Respectively there are two different phases of an angiogenic process occurring in the liver cirrhosis. Initially, the formation of blood vessels occurs in develop ing incomplete septa in which concomitant expression of VEGF, Flk1, and Tie2 is restricted by HSCs. In a later phase, angiogenesis occurs in large bridging septa and the expression of this proangiogenic panel is limited to endothelial cells and aims to stabilize the newly formed blood vessels [52] . Some of them occur mainly along areas of active inflammation and fibrous septa, probably favors inflammation, tissue repair, and gives rise to intrahepatic shunts. Some of them probably needed for compensation of insufficient intrahepatic blood flow. Other forms intrahepatic shunts bypassing sinusoids and draining blood from the portal to the central venule.
Although they perform the decompression role, they can lead to liver dysfunction due to declining oxygen delivery and nutrients to the liver tissues and limiting the free exchange between hepatocytes and sinusoids [53] . During last years it has been found that endothelial progenitor cells produced by stem cells of the bone marrow are capable of causing in situ neovascularization in both physiological and pathological conditions (post natal vasculogenesis). In particular, they may play an important paracrine role in liver angiogenesis by stimulating resident SECs through as factors as PDGF and VEGF in liver cirrhosis [54] . However, their angiogenic ability is significantly reduced in patients in this category, especially with severe hepatic dysfunction. Perhaps this is because chronic inflammation stimulates the release of angiogenic factors by resident HSCs and SECs, and inhibits the endothelial progenitor cells mobilization into the bloodstream [55] .
CONCLUSION
Endothelial dysfunction and impaired paracrine inter action between activated HSCs and SECs, as well as sinusoidal remodeling and capillarization play an important role in improving the HVR to portal blood flow, adding structural changes associated with diffuse fibrosis and regenerative nodules in liver cirrhosis. The development of intrahepatic angiogenesis can be regarded as a compensatory mechanism that is aimed at decompression of the portal system. However, the newly formed vessels carrying blood to bypass the sinusoids are unable to provide oxygen and nutrients to the liver tissue which leads to progression of the disease. A comprehensive assessment of morphological and functional changes of hepatic vessels in the liver cirrhosis might allow to develop some new correction methods of its specific hemodynamic disorders. More over, it could help to enhance the effectiveness of therapeutic interventions aimed at the prevention of portal hypertension complications.
